KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies

Qing Wen, Philip D. Dunne, Paul G. O’Reilly, Gerald Li, Tony Bjourson, Darragh G. McArt, Peter W. Hamilton, Shu-Dong Zhang*

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)
51 Downloads (Pure)


Colorectal cancer (CRC) is a life-threatening disease with high prevalence and mortality worldwide. The KRAS oncogene is mutated in approximately 40% of CRCs. While antibody based EGFR inhibitors (cetuximab and panitumumab) represent a major treatment strategy for advanced KRAS wild type (KRAS-WT) CRCs, there still remains no effective therapeutic course for advanced KRAS mutant (KRAS-MT) CRC patients.

In this study, we employed a novel and comprehensive approach of gene expression connectivity mapping (GECM) to identify candidate compounds to target KRAS-MT tumors. We first created a combined KRAS-MT gene signature with 248 ranked significant genes using 677 CRC clinical samples. A series of 248 sub-signatures was then created containing an increasing number of the top ranked genes. As an input to GECM analysis, each sub-signature was translated into a statistically significant therapeutic drugs list, which was finally combined to obtain a single list of significant drugs.

We identify four antihypertensive angiotensin II receptor blockers (ARBs) within the top 30 significant drugs indicating that these drugs have a mechanism of action that can alter the KRAS-MT CRC oncogenic signaling. A hypergeometric test (p-value = 6.57 × 10−6) confirmed that ARBs are significantly enriched in our results. These findings support the hypothesis that ARB antihypertensive drugs may directly block KRAS signaling resulting in improvement in patient outcome or, through a reversion to a KRAS wild-type phenotype, improve the response to anti-EGFR treatment. Antihypertensive angiotensin II receptor blockers are therefore worth further investigation as potential therapeutic candidates in this difficult category of advanced colorectal cancers.
Original languageEnglish
Pages (from-to)3206-3225
Number of pages19
Issue number2
Early online date10 Dec 2016
Publication statusPublished (in print/issue) - 10 Jan 2017


  • connectivity mapping
  • differentially expressed genes
  • colorectal cancer
  • KRAS mutation
  • FDA approved drugs
  • angiotensin II receptor blockers (ARBs)


Dive into the research topics of 'KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies'. Together they form a unique fingerprint.

Cite this